Meeder Asset Management Inc. Has $663,000 Stake in United Therapeutics Corporation (NASDAQ:UTHR)

Meeder Asset Management Inc. boosted its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 11,855.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,152 shares of the biotechnology company’s stock after purchasing an additional 2,134 shares during the quarter. Meeder Asset Management Inc.’s holdings in United Therapeutics were worth $663,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Allianz Asset Management GmbH grew its holdings in shares of United Therapeutics by 96.9% during the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock valued at $20,832,000 after buying an additional 33,254 shares during the last quarter. Cerity Partners LLC lifted its position in United Therapeutics by 30.4% in the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $4,098,000 after acquiring an additional 2,702 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in United Therapeutics by 11.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company’s stock valued at $1,129,000 after purchasing an additional 376 shares during the last quarter. Concurrent Investment Advisors LLC acquired a new position in United Therapeutics during the 1st quarter valued at about $227,000. Finally, Nepsis Inc. increased its holdings in United Therapeutics by 6.7% during the 1st quarter. Nepsis Inc. now owns 58,574 shares of the biotechnology company’s stock worth $18,057,000 after purchasing an additional 3,653 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In related news, Director Richard Giltner sold 3,036 shares of the company’s stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the transaction, the director owned 19,384 shares in the company, valued at approximately $5,613,606.40. This represents a 13.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James Edgemond sold 12,000 shares of the firm’s stock in a transaction on Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the sale, the chief financial officer directly owned 8,118 shares of the company’s stock, valued at $2,641,353.66. This represents a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,681 shares of company stock worth $24,628,589. Company insiders own 10.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on UTHR shares. Wells Fargo & Company restated an “equal weight” rating and issued a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Cantor Fitzgerald assumed coverage on United Therapeutics in a research report on Monday, June 2nd. They issued an “overweight” rating and a $405.00 price target for the company. JPMorgan Chase & Co. cut their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a report on Tuesday, July 8th. Bank of America reduced their target price on shares of United Therapeutics from $321.00 to $315.00 and set a “neutral” rating for the company in a research note on Wednesday, June 11th. Finally, UBS Group lowered their target price on shares of United Therapeutics from $410.00 to $385.00 and set a “buy” rating for the company in a report on Monday, June 30th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $383.08.

United Therapeutics Stock Performance

UTHR opened at $297.56 on Wednesday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $417.82. The firm has a 50-day moving average of $299.63 and a 200 day moving average of $314.91. The firm has a market cap of $13.42 billion, a P/E ratio of 11.87, a PEG ratio of 6.50 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts’ consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The firm had revenue of $794.40 million for the quarter, compared to analysts’ expectations of $726.82 million. During the same period in the previous year, the company earned $6.17 earnings per share. The company’s quarterly revenue was up 17.2% on a year-over-year basis. Equities research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.